Related Experiment Video
Updated: Mar 21, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Production, characterization, and in vitro effects of a novel monoclonal antibody against Mig-7
Satita Tapaneeyakorn1, Warangkana Chantima2, Charin Thepthai2
1National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency (NSTDA), Pathumthani 12120, Thailand.
Abstract:
Development of new cancer therapies based on specific recognition of molecules in cancer cells is a significant challenge, as this requires identification of such molecules (molecular targets) and subsequent development of high-affinity, selective binders (targeting molecules). While several molecular targets for cancer therapies are currently under evaluation in clinical trials, greater selectivity for cancer cells over normal cells is required to enhance efficacy. Migration-inducing gene 7 (Mig-7), a membrane protein found in various types of carcinoma cells, is a cancer-specific biomarker and a promising molecular target for targeted cancer therapies. The purpose of this study was to produce and characterize a novel monoclonal antibody (mAb) raised against an N-terminal peptide of human Mig-7 (Mig-7(1-30)). The Mig-7(1-30) peptide was conjugated with a KLH carrier protein for immunization, and the mAb specific to Mig-7 (STmAb-1) was produced using hybridoma technology. Western blot analysis showed that STmAb-1 specifically reacted with a 23-kDa Mig-7 protein expressed in cancer cell lines, and, crucially, not with primary human fibroblasts. The affinity constant (Kaff) of STmAb-1, as measured by non-competitive enzyme immunoassay, was 1.31 × 10(9) M(-1), indicating high mAb affinity against Mig-7. Immunofluorescence assays demonstrated that STmAb-1 could specifically recognize Mig-7 expressed in cancer cell lines, but not in primary human fibroblasts and keratinocytes. Moreover, STmAb-1 inhibited the growth of MCF7 and HeLa cell lines in contrast to primary human fibroblasts, highlighting its potential usefulness in the development of new cancer therapeutics.
Insights
Researchers developed a novel monoclonal antibody (STmAb-1) targeting Migration-inducing gene 7 (Mig-7), a cancer-specific protein. This antibody shows high affinity and selectively inhibits cancer cell growth, offering potential for new targeted cancer therapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Targeted cancer therapies require specific molecular targets and high-affinity binders.
- Migration-inducing gene 7 (Mig-7) is a cancer-specific membrane protein and a promising therapeutic target.
- Enhanced selectivity for cancer cells over normal cells is crucial for improving therapeutic efficacy.
Purpose of the Study:
- To produce and characterize a novel monoclonal antibody (mAb) against the N-terminal peptide of human Mig-7 (Mig-7(1-30)).
- To evaluate the specificity, affinity, and therapeutic potential of the developed mAb (STmAb-1).
Main Methods:
- Production of a monoclonal antibody (STmAb-1) using hybridoma technology against a Mig-7(1-30) peptide conjugated to KLH.
- Western blot analysis to assess STmAb-1 reactivity with Mig-7 protein in cancer cell lines versus primary fibroblasts.
- Non-competitive enzyme immunoassay to determine the affinity constant (Kaff) of STmAb-1.
- Immunofluorescence assays to confirm STmAb-1 specificity for Mig-7 in different cell types.
- In vitro cell growth inhibition assays using cancer cell lines and primary fibroblasts.
Main Results:
- STmAb-1 specifically recognized a 23-kDa Mig-7 protein in cancer cell lines, but not in primary human fibroblasts.
- The antibody exhibited high affinity for Mig-7, with an affinity constant (Kaff) of 1.31 × 10^9 M⁻¹.
- Immunofluorescence confirmed STmAb-1's specific recognition of Mig-7 in cancer cells, excluding normal fibroblasts and keratinocytes.
- STmAb-1 demonstrated inhibition of MCF7 and HeLa cancer cell growth, while not affecting primary human fibroblasts.
Conclusions:
- STmAb-1 is a highly specific and high-affinity monoclonal antibody targeting the cancer-specific protein Mig-7.
- The antibody's ability to selectively target cancer cells and inhibit their growth highlights its potential as a novel therapeutic agent.
- Further development of STmAb-1 could lead to more effective and selective targeted cancer therapies.
